Similar articles

• Response to Dikkers letter to the editor regarding "systematic review of intralesional cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis".

  Clamp PJ, Saunders MW. Clamp PJ, et al. Int J Pediatr Otorhinolaryngol. 2013 Oct;77(10):1789. doi: 10.1016/j.ijporl.2013.08.017. Epub 2013 Aug 27. Int J Pediatr Otorhinolaryngol. 2013. PMID: 24021212 No abstract available.
• Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®).

  Tjon Pian Gi RE, Dietz A, Djukic V, Eckel HE, Friedrich G, Golusinski W, Hantzakos A, Lawson G, Remacle M, Rihkanen H, Dikkers FG. Tjon Pian Gi RE, et al. Eur Arch Otorhinolaryngol. 2012 Feb;269(2):361-2. doi: 10.1007/s00405-011-1804-7. Epub 2011 Oct 22. Eur Arch Otorhinolaryngol. 2012. PMID: 22020697 Free PMC article. No abstract available.
• Current use of intralesional cidofovir for recurrent respiratory papillomatosis.

  Derkay CS, Volsky PG, Rosen CA, Pransky SM, McMurray JS, Chadha NK, Froehlich P. Derkay CS, et al. Laryngoscope. 2013 Mar;123(3):705-12. doi: 10.1002/lary.23673. Epub 2012 Oct 15. Laryngoscope. 2013. PMID: 23070868
• Intralesional cidofovir as adjuvant for the successful management of aggressive respiratory papillomatosis in an infant.

  Durvasula VS, Richter GT. Durvasula VS, et al. Int J Pediatr Otorhinolaryngol. 2013 Nov;77(11):1912-5. doi: 10.1016/j.ijporl.2013.08.035. Epub 2013 Sep 8. Int J Pediatr Otorhinolaryngol. 2013. PMID: 24063771 Review.
• Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir.

  Fusconi M, Grasso M, Greco A, Gallo A, Campo F, Remacle M, Turchetta R, Pagliuca G, DE Vincentiis M. Fusconi M, et al. Acta Otorhinolaryngol Ital. 2014 Dec;34(6):375-81. Acta Otorhinolaryngol Ital. 2014. PMID: 25762828 Free PMC article. Review.